meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic/advanced RCC (mRCC) - 1st line (L1)
11
mRCC - L1 - PDL1 negative
1
mRCC - L1 - PDL1 positive
4
<span style="margin-left: 0em;">immune chekpoint inhibitors</span>
<span style="margin-left: 1em;">anti-PD-(L)1</span>
<span style="margin-left: 2em;">atezolizumab based treatment</span>
<span style="margin-left: 3em;">atezolizumab plus bevacizumab <i class='fa fa-circle' style='color: royalblue; font-size: 10px;'></i></span>
<span style="margin-left: 0em;">VEGF(R) inhibitor</span>
<span style="margin-left: 1em;">sunitinib <i class='fa fa-circle' style='color: royalblue; font-size: 10px;'></i></span>
Select endpoint...
progression or deaths (PFS) (1)
objective responses (ORR) (1)
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
insufficient data
Evidence network for EEEE
sunitinib
atezolizumab plus bevacizumab
direct evidence
network meta-analysis
comet plot
result box
odds ratio
A
B
0.5
1.5
1.0
odds ratio for A vs. B
and half 95% CI
T
vs.
C
sunitinib
atezolizumab plus bevacizumab
sunitinib
---
NA
atezolizumab plus bevacizumab
NA
---
pathologies: 178 - treatments: 602
result logic
×
Study list